Latest news

Adalvo is excited to announce the introduction of Apalutamide to our Oncology Portfolio. Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a...

Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets.  Based on the...

Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European...

Adalvo proudly announces the addition of Mirabegron/Solifenacin Prolonged Release Tablets to our product list, set to be submitted for regulatory approval in Q1 2025. Developed in collaboration with one of our strategic...

Aztiq, a prominent healthcare investor led by Founder and Chairman Róbert Wessman, has finalized an agreement in Q1 2024 with Innobic (Asia) Company Limited (“Innobic”), the life science arm of...

Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024. Our product has...

Adalvo is thrilled to announce the successful launch of Desmopressin in multiple countries across Europe, in collaboration with key strategic partners. Developed based on the reference brand Minirin Melt from Ferring, Desmopressin...

Adalvo is delighted to announce the successful completion of the FED and Fasting Pilot BE Study for Fidaxomicin Film Coated Tablets 200mg. Developed in collaboration with one of our strategic partners,...

Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tablets to our product list. Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as...

Adalvo is pleased to announce the restart of the DCP procedure for Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024. Based on the reference brand...

Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral Solution to our product portfolio. Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid...

Adalvo is delighted to announce the restart of the DCP procedure for Dalbavancin powder, with an estimated approval date in May 2024. This antibiotic niche product has been developed based on...

Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel. Our product, based on the reference brand Imnovid, is indicated for the...

Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024. As a generic and bioequivalent...

Adalvo stands in solidarity with the global community on Rare Disease Day, today February 29th, reminding us of the profound challenges faced by millions worldwide battling rare diseases, where access to...

Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets. This product has been developed in collaboration with one of our strategic partners,...

Adalvo is pleased to announce that Apremilast 10mg, 20mg, and 30mg film-coated tablets has received its first approval in Europe. Having gained approval in December 2023, this positions Adalvo as the...

Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine Oral Solution 10mg/ml, developed in close collaboration with one of our strategic partners. This product represents a value-added version of Lisdexamfetamine...

Adalvo is pleased to announce the successful DCP approval for Nintedanib 100mg & 150mg Soft Gel Capsules. This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for...

Adalvo is proud to announce the successful launch of Desmopressin Sublingual Tablets in France, solidifying our position as the first generic to introduce this innovative medication in the European Union. This accomplishment...

On World Cancer Day, Adalvo proudly stands at the forefront of the global battle against cancer. As we commemorate this significant day, we invite you to explore Adalvo's comprehensive Oncology...